These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26388424)

  • 1. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
    Jairath V; Khanna R; Zou GY; Stitt L; Mosli M; Vandervoort MK; D'Haens G; Sandborn WJ; Feagan BG; Levesque BG
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1200-10. PubMed ID: 26388424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score.
    Jairath V; Jeyarajah J; Zou G; Parker CE; Olson A; Khanna R; D'Haens GR; Sandborn WJ; Feagan BG
    Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):63-70. PubMed ID: 30343116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
    Schreiber S; Hanauer SB; Sandborn WJ; Barrett K
    J Crohns Colitis; 2020 Sep; 14(9):1274-1281. PubMed ID: 32179906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
    Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
    Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
    Feagan BG; Sandborn WJ; D'Haens G; Pola S; McDonald JWD; Rutgeerts P; Munkholm P; Mittmann U; King D; Wong CJ; Zou G; Donner A; Shackelton LM; Gilgen D; Nelson S; Vandervoort MK; Fahmy M; Loftus EV; Panaccione R; Travis SP; Van Assche GA; Vermeire S; Levesque BG
    Gastroenterology; 2013 Jul; 145(1):149-157.e2. PubMed ID: 23528626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
    Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
    J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
    Jharap B; Sandborn WJ; Reinisch W; D'Haens G; Robinson AM; Wang W; Huang B; Lazar A; Thakkar RB; Colombel JF
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1082-92. PubMed ID: 26381802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
    Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
    Inflamm Bowel Dis; 2009 Jan; 15(1):1-8. PubMed ID: 18671232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials.
    Sun H; Lee JJ; Papadopoulos EJ; Lee CS; Nelson RM; Sachs HC; Rodriguez WJ; Mulberg AE
    J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):12-7. PubMed ID: 24121142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1050-1060.e9. PubMed ID: 36029969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
    Yoshimura N; Watanabe M; Motoya S; Tominaga K; Matsuoka K; Iwakiri R; Watanabe K; Hibi T;
    Gastroenterology; 2015 Dec; 149(7):1775-1783.e2. PubMed ID: 26327130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
    Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.
    Langhorst J; Varnhagen I; Schneider SB; Albrecht U; Rueffer A; Stange R; Michalsen A; Dobos GJ
    Aliment Pharmacol Ther; 2013 Sep; 38(5):490-500. PubMed ID: 23826890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
    Zakko SF; Gordon GL; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
    Postgrad Med; 2016; 128(3):273-81. PubMed ID: 26861051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
    Sandborn WJ; Bhandari BR; Randall C; Younes ZH; Romanczyk T; Xin Y; Wendt E; Chai H; McKevitt M; Zhao S; Sundy JS; Keshav S; Danese S
    J Crohns Colitis; 2018 Aug; 12(9):1021-1029. PubMed ID: 29767728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.